000124231 001__ 124231
000124231 005__ 20240228145500.0
000124231 0247_ $$2doi$$a10.1186/s40164-017-0065-6
000124231 0247_ $$2pmid$$apmid:28194306
000124231 0247_ $$2pmc$$apmc:PMC5297221
000124231 0247_ $$2altmetric$$aaltmetric:16659696
000124231 037__ $$aDKFZ-2017-01127
000124231 041__ $$aeng
000124231 082__ $$a610
000124231 1001_ $$aSchönsteiner, Stefan S$$b0
000124231 245__ $$aA randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises.
000124231 260__ $$aLondon$$bBiomed Central$$c2017
000124231 3367_ $$2DRIVER$$aarticle
000124231 3367_ $$2DataCite$$aOutput Types/Journal article
000124231 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1510842017_26078
000124231 3367_ $$2BibTeX$$aARTICLE
000124231 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124231 3367_ $$00$$2EndNote$$aJournal Article
000124231 520__ $$aChemotherapy-induced polyneuropathy (CIPN) is a common toxicity after chemotherapy, immunomodulatory drugs or proteasome inhibitors, which is difficult to treat and may also have impact on quality of life. The objective of the study was to evaluate whole-body vibration (WBV) on the background of an integrated program (IP) including massage, passive mobilization and physical exercises on CIPN.In an exploratory phase-2 study patients with CIPN (NCI CTC grade 2/3) were randomized for WBV plus IP (experimental) to IP alone (standard). 15 training sessions within 15 weeks were intended. As primary endpoint we used chair-rising test (CRT) to assess physical fitness and coordination. In addition, locomotor and neurological tests and self-assessment tools were performed.A total 131 patients with CIPN were randomized (standard, n = 65; experimental, n = 66). The median age was 60 (range 24-71) years; 44 patients had haematological neoplasms and 87 solid tumors. At baseline, all patients presented with an abnormal CRT. Fifteen (standard) and 22 (experimental) patients left the program due to progression/relapse or concomitant disease. There was no significant difference in the proportion of patients with normal CRT (<10 s) at follow up between experimental (68%) and standard (56%) (p = 0.20). All patients experienced less symptoms and pain (p < 0.001) and had improved CRT (p < 0.001) over time. WBV was significantly associated with a higher reduction of time needed for CRT (p = 0.02) and significantly improved warm-detection-threshold comparing baseline to follow-up assessment (p = 0.02).Whole-body vibration on the background of an IP may improve physical fitness and coordination in patients suffering from CIPN. Trial registration Retrospectively registered at http://www.iscrtn.com (ISRCTN 51361937) and http://www.clinicaltrials.gov (NCT02846844).
000124231 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000124231 588__ $$aDataset connected to CrossRef, PubMed,
000124231 7001_ $$aBauder Mißbach, Heidi$$b1
000124231 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b2$$udkfz
000124231 7001_ $$aMack, Silja$$b3
000124231 7001_ $$aHamel, Thomas$$b4
000124231 7001_ $$aOrth, Michael$$b5
000124231 7001_ $$aLandwehrmeyer, Bernhard$$b6
000124231 7001_ $$aSüßmuth, Sigurd D$$b7
000124231 7001_ $$aGeitner, Carolin$$b8
000124231 7001_ $$aMayer-Steinacker, Regine$$b9
000124231 7001_ $$aRiester, Anneliese$$b10
000124231 7001_ $$aProkein, Andrea$$b11
000124231 7001_ $$aErhardt, Elfriede$$b12
000124231 7001_ $$aKunecki, Jelena$$b13
000124231 7001_ $$aEisenschink, Anna M$$b14
000124231 7001_ $$aRawer, Rainer$$b15
000124231 7001_ $$aDöhner, Hartmut$$b16
000124231 7001_ $$aKirchner, Elisabeth$$b17
000124231 7001_ $$0P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aSchlenk, Richard$$b18$$eLast author
000124231 773__ $$0PERI:(DE-600)2669066-4$$a10.1186/s40164-017-0065-6$$gVol. 6, no. 1, p. 5$$n1$$p5$$tExperimental hematology & oncology$$v6$$x2162-3619$$y2017
000124231 909CO $$ooai:inrepo02.dkfz.de:124231$$pVDB
000124231 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000124231 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000124231 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000124231 9141_ $$y2017
000124231 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124231 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124231 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000124231 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000124231 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000124231 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000124231 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000124231 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124231 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index
000124231 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124231 9201_ $$0I:(DE-He78)G040-20160331$$kG040$$lKlinische Studienzentrale$$x0
000124231 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000124231 980__ $$ajournal
000124231 980__ $$aVDB
000124231 980__ $$aI:(DE-He78)G040-20160331
000124231 980__ $$aI:(DE-He78)C060-20160331
000124231 980__ $$aUNRESTRICTED